
Multidisciplinary institutional guidelines, more education and advocacy from pharmacists, national consensus guidance, and clinical trials that use the newer equations are needed in the hematology/oncology space.

Multidisciplinary institutional guidelines, more education and advocacy from pharmacists, national consensus guidance, and clinical trials that use the newer equations are needed in the hematology/oncology space.

The panelists recommend cross-comparing equations, deciding doses with the care team, and watching for patients at high risk of inaccurate estimates when moving chemotherapy dosing from Cockcroft-Gault to eGFR.

Moving from Cockcroft-Gault to race-agnostic estimated glomerular filtration rate (eGFR) for drug dosing is slowed by older trial data, inconsistent package inserts, gaps in education, and the work of updating EHR order sets.

Peer Reviewed
This article discusses clinical data for noncovalent Bruton tyrosine kinase inhibitors (BTKis), novel strategies in CLL, and the practical management of BTKi toxicities.

Peer Reviewed
This article provides an overview of data supporting the utility of covalent Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia and details important considerations when choosing among agents.

Integrating immunotherapies will continue to improve patient outcomes and quality of life.